Recurring Licensing Business ModelA licensing/subscription model to research, biotech and healthcare customers creates recurring revenue and higher customer lifetime value. This durable revenue mix supports predictable cash inflows, easier forecasting, and long-term customer relationships via renewals and service contracts.

Specialized Product-market FitQlucore's focused platform for high-dimensional omics analysis addresses a specialized niche with technical barriers and domain-specific workflows. This reduces competition from generic analytics tools and creates stickiness among research and diagnostics customers, supporting long-term demand.

Low Financial LeverageLimited leverage reduces solvency risk and gives management flexibility to navigate restructuring, invest in product development, or pursue partnerships without heavy interest burdens. Low debt preserves strategic optionality during prolonged turnarounds.

Bears Say

Declining Revenue TrendA near-20% revenue contraction signals weakening product adoption or customer renewals. Sustained top-line decline erodes scale, reduces R&D and sales capacity, and risks a shrinking installed base—undermining the advantages of a subscription model over a multi-month horizon.

Persistent Unprofitability And Negative MarginsNegative gross and net margins indicate the core business is not covering direct costs and operating expenses. Without structural margin improvement, the company cannot sustainably fund growth or reinvest in product capabilities, pressuring long-term competitiveness.

Weak Cash Generation And Cash ConversionConsistent negative operating and free cash flows show the company struggles to convert revenue into usable cash. Over months, this limits investment, forces external financing or dilution, and constrains the ability to scale sales, support, or product development.

QCORE FAQ

What was Qlucore AB’s price range in the past 12 months?

Qlucore AB lowest stock price was kr0.25 and its highest was kr2.24 in the past 12 months.

What is Qlucore AB’s market cap?

Currently, no data Available

When is Qlucore AB’s upcoming earnings report date?

Qlucore AB’s upcoming earnings report date is Feb 26, 2026 which is in 8 days.

How were Qlucore AB’s earnings last quarter?

Qlucore AB released its earnings results on Nov 27, 2025. The company reported -kr0.775 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.775.

Is Qlucore AB overvalued?

According to Wall Street analysts Qlucore AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Qlucore AB pay dividends?

Qlucore AB does not currently pay dividends.

What is Qlucore AB’s EPS estimate?

Qlucore AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Qlucore AB have?

Qlucore AB has 42,900,500 shares outstanding.

What happened to Qlucore AB’s price movement after its last earnings report?

Qlucore AB reported an EPS of -kr0.775 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.25%.

Which hedge fund is a major shareholder of Qlucore AB?

Currently, no hedge funds are holding shares in SE:QCORE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Qlucore AB

Qlucore AB (publ) provides bioinformatics data analysis tools for research and precision diagnostics in Sweden and internationally. Its products include Qlucore Omics Explorer, a bioinformatics AI software for research in life science, biotech, food, and plant industries, as well as academia; Qlucore Diagnostics, a software platform for multi-omics companion and precision diagnostics; and Qlucore Insights, a software for clinical data analysis. Qlucore AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.